Literature DB >> 1360713

P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma.

S D Flynn1, J R Murren, W M Kirby, J Honig, L Kan, B K Kinder.   

Abstract

BACKGROUND: The response of adrenocortical carcinoma (ACC) to adjuvant chemotherapy has been disappointing with no significant impact on survival. The normal adrenal cortex has very high levels of P-glycoprotein, an energy-dependent efflux pump of a variety of structurally unrelated chemotherapeutic agents. P-glycoprotein has been implicated as a cause of multidrug resistance in a variety of neoplasms. The purpose of this study was to evaluate P-glycoprotein expression in ACC.
METHODS: Eleven patients with ACC had paraffin-embedded tumor evaluated for P-glycoprotein expression. These were analyzed by immunohistochemistry assay with a battery of four anti-P-glycoprotein antibodies (MRK-16, JSB-1, UIC-2, MDR).
RESULTS: All eleven cases showed intense, predominantly membrane immunoreactivity for P-glycoprotein. In 10 of the cases, most tumor cells were immunoreactive with at least three antibodies, and six of 11 cases were positive for all four antibodies. In this small series no correlation existed between P-glycoprotein expression and tumor grade, stage of disease, or survival.
CONCLUSIONS: All 11 cases of ACC studied showed P-glycoprotein expression, which was similar to the normal adrenal cortex. This possible mechanism of multidrug resistance may help explain the significant chemoresistance seen in ACC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360713

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

Review 1.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 2.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 3.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

4.  Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Authors:  Teresa Gagliano; Erica Gentilin; Katiuscia Benfini; Carmelina Di Pasquale; Martina Tassinari; Simona Falletta; Carlo Feo; Federico Tagliati; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

5.  Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.

Authors:  Motohiko Aiba; Mariko Fujibayashi
Journal:  Endocr Pathol       Date:  2005       Impact factor: 4.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.